Assessment of platelet reactivity with anti platelet agent (clopidogrel) after two drugs formulation PLAVIX® and PLAGERINE

Abstract

Cardiovascular disease remains the main cause of mortality. Antiplatelet therapy is the main druguse in the management of coronary artery disease. Several million of people receivedcolpidogril,however the cost of the drug that might 3-4 dollars daily for the brand company sanofi .pharmaciesstart to sell cheaper generic from Indian origin .assessment of platelet function after two drugs(plavixand plagrine) by multiple electrode platelet aggregometry (MEA) shows no difference of both drugson the multiplate activity,this is assessted by prospective cross sectional study included 28 patientsrandomized to receive either plavix or plagrine, there is no significant differences regarded the effectsof some risk factors in outcome in both group plavix and plagrine.